Peripheral administration of an anti-TNF-α receptor fusion protein counteracts the amyloid induced elevation of hippocampal TNF-α levels and memory deficits in mice

Neurochemistry International

Volumn 72, Issue 1, 2014, Pages 10-13

  Detrait, E R ^a   Danis, B ^a   Lamberty, Y ^a   Foerch, P ^a  

^a UCB PHARMA   (Belgium)

Author keywords

Alzheimer disease; Biologics; Neuroinflammation; TNF

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; ETANERCEPT; NDC 58406 425 34; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; AMYLOID; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (25-35); HYBRID PROTEIN; PEPTIDE FRAGMENT; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 2;

ALZHEIMER DISEASE; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN LEVEL; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HIPPOCAMPUS; LATENT PERIOD; LONG TERM MEMORY; MALE; MEMORY CONSOLIDATION; MOUSE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; SYSTEMIC THERAPY; WORKING MEMORY; ANIMAL; ANTAGONISTS AND INHIBITORS; AVOIDANCE BEHAVIOR; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; MEMORY DISORDERS; METABOLISM; PSYCHOMOTOR PERFORMANCE; SHORT TERM MEMORY; TOXICITY;

AMYLOID; AMYLOID BETA-PEPTIDES; ANIMALS; AVOIDANCE LEARNING; MEMORY DISORDERS; MEMORY, SHORT-TERM; MICE; PEPTIDE FRAGMENTS; PSYCHOMOTOR PERFORMANCE; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; TNF RECEPTOR-ASSOCIATED FACTOR 2;

EID: 84899516623     PISSN: 01970186     EISSN: 18729754     Source Type: Journal    
DOI: 10.1016/j.neuint.2014.04.001     Document Type: Article

References (33)

1. T. Alkam, A. Nitta, H. Mizoguchi, K. Saito, M. Seshima, A. Itoh, K. Yamada, and T. Nabeshima Restraining tumor necrosis factor-alpha by thalidomide prevents the amyloid beta-induced impairment of recognition memory in mice Behav. Brain Res. 189 1 2008 100 106
2. M. Bacher, C. Depboylu, Y. Du, C. Noelker, W.H. Oertel, T. Behr, G. Henriksen, M. Behe, and R. Dodel Peripheral and central biodistribution of (1 1 1) in-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease Neurosci. Lett. 449 3 2009 240 245
3. W.A. Banks Are the extracellular [correction of extracellular] pathways a conduit for the delivery of therapeutics to the brain? Curr. Pharm. Des. 10 12 2004 1365 1370
4. F. Bard, C. Cannon, R. Barbour, R.L. Burke, D. Games, H. Grajeda, T. Guido, K. Hu, J. Huang, K. Johnson-Wood, K. Khan, D. Kholodenko, M. Lee, I. Lieberburg, R. Motter, M. Nguyen, F. Soriano, N. Vasquez, K. Weiss, B. Welch, P. Seubert, D. Schenk, and T. Yednock Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat. Med. 6 8 2000 916 919
5. F. Bard, M. Fox, S. Friedrich, P. Seubert, D. Schenk, G.G. Kinney, and T. Yednock Sustained levels of antibodies against Aβ in amyloid-rich regions of the CNS following intravenous dosing in human APP transgenic mice Exp. Neurol. 238 1 2012 38 43
6. F. Chavant, J. Deguil, S. Pain, I. Ingrand, S. Milin, B. Fauconneau, M.C. Pérault-Pochat, and C. Lafay-Chebassier Imipramine, in part through tumor necrosis factor alpha inhibition, prevents cognitive decline and beta-amyloid accumulation in a mouse model of Alzheimer's disease J. Pharmacol. Exp. Ther. 332 2 2010 505 514
7. X. Cheng, L. Yang, P. He, R. Li, and Y. Shen Differential activation of tumor necrosis factor receptors distinguishes between brains from Alzheimer's disease and non-demented patients J. Alzheimers Dis. 19 2 2010 621 630
8. Chou, 2010. American College of Rheumatology, Abtract 640, November.
9. R.B. DeMattos, K.R. Bales, D.J. Cummins, J.C. Dodart, S.M. Paul, and D.M. Holtzman Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease Proc. Natl. Acad. Sci. USA 98 15 2001 8850 8855
10. D. Di Bona, G. Candore, i.C. Francesch, F. Licastro, G. Colonna-Romano, C. Cammà, D. Lio, and C. Caruso Systematic review by meta-analyses on the possible role of TNF-alpha polymorphisms in association with Alzheimer's disease Brain Res. Rev. 61 2 2009 60 68
11. A. Diaz, D. Limon, R. Chávez, E. Zenteno, and J. Guevara Aβ25-35 injection into the temporal cortex induces chronic inflammation that contributes to neurodegeneration and spatial memory impairment in rats J. Alzheimers Dis. 30 3 2012 505 522
12. S.P. Gabbita, M.K. Srivastava, P. Eslami, M.F. Johnson, N.K. Kobritz, D. Tweedie, N.H. Greig, F.P. Zemlan, S.P. Sharma, and M.E. Harris-White Early intervention with a small molecule inhibitor for tumor necrosis factor-α prevents cognitive deficits in a triple transgenic mouse model of Alzheimer's disease J. Neuroinflamm. 25 9 2012 99
13. L.L. Guo, Z.Z. Guan, Y. Huang, Y.L. Wang, and J.S. Shi The neurotoxicity of β-amyloid peptide toward rat brain is associated with enhanced oxidative stress, inflammation and apoptosis, all of which can be attenuated by scutellarin Exp. Toxicol. Pathol. 65 5 2013 579 584
14. Imbimbo, B.P., Solfrizzi, V., Panza, F., 2010. Are NSAIDs useful to treat Alzheimer's disease or mild cognitive impairment? Front. Aging Neurosci. 21(2), pii:19.
15. B.A. In 't Veld, L.J. Launer, A.W. Hoes, A. Ott, A. Hofman, M.M. Breteler, and B.H. Stricker NSAIDs and incident Alzheimer's disease, the Rotterdam study Neurobiol. Aging 19 6 1998 607 611
16. M.C. Janelsins, M.A. Mastrangelo, K.M. Park, l.K.L. Sudo, W.C. Narrow, S. Oddo, F.M. LaFerla, L.M. Callahan, H.J. Federoff, and W.J. Bowers Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3 × Tg-AD mice Am. J. Pathol. 173 6 2008 1768 1782
17. 1 receptor agonist, in a nontransgenic mouse model of Alzheimer's disease Neuropsychopharmacology 2013 9 2013 1706 1723
18. T. Maurice, B.P. Lockhart, and A. Privat Amnesia induced in mice by centrally administered beta-amyloid peptides involves cholinergic dysfunction Brain Res. 706 2 1996 181 193
19. T. Maurice, B.P. Lockhart, T.P. Su, and A. Privat Reversion of beta 25-35-amyloid peptide-induced amnesia by NMDA receptor-associated glycine site agonists Brain Res. 731 1-2 1996 249 253
20. T. Maurice, T.P. Su, and A. Privat Sigma1 (sigma 1) receptor agonists and neurosteroids attenuate B25-35-amyloid peptide-induced amnesia in mice through a common mechanism Neuroscience 83 2 1998 413 428
21. S.L. Montgomery, M.A. Mastrangelo, D. Habib, W.C. Narrow, S.A. Knowlden, T.W. Wright, and W.J. Bowers Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNF-α suppressive therapeutic strategies in the brain Am. J. Pathol. 179 4 2011 2053 2070
22. S.L. Montgomery, W.C. Narrow, M.A. Mastrangelo, J.A. Olschowka, M.K. O'Banion, and J. Bowers Chronic neuron- and age-selective down-regulation of TNF receptor expression in triple-transgenic Alzheimer's disease mice leads to significant modulation of amyloid- and tau-related pathologies Am. J. Pathol. S0002-9440 13 2013 00209-05
23. R.B. Pepinsky, Z. Shao, B. Ji, Q. Wang, G. Meng, L. Walus, X. Lee, Y. Hu, C. Graff, E. Garber, W. Meier, and S. Mi Exposure levels of anti-LINGO-1 Li81 antibody in the central nervous system and dose-efficacy relationships in rat spinal cord remyelination models after systemic administration J. Pharmacol. Exp. Ther. 339 2 2011 519 529
24. V.H. Perry The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease Brain Behav. Immun. 18 5 2004 407 413
25. V.H. Perry Contribution of systemic inflammation to chronic neurodegeneration Acta Neuropathol. 120 3 2010 277 286
26. V.H. Perry, T.A. Newman, and C. Cunningham The impact of systemic infection on the progression of neurodegenerative disease Nat. Rev. Neurosci. 4 2 2003 103 112
27. J.Q. Shi, W. Shen, J. Chen, B.R. Wang, L.L. Zhong, Y.W. Zhu, H.Q. Zhu, Q.Q. Zhang, Y.D. Zhang, and J. Xu Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains Brain Res. 1368 2011 239 247
28. D. Tweedie, R.A. Ferguson, K. Fishman, K.A. Frankola, H. Van Praag, H.W. Holloway, W. Luo, Y. Li, L. Caracciolo, I. Russo, S. Barlati, B. Ray, D.K. Lahiri, F. Bosetti, N.H. Greig, and S. Rosi Tumor necrosis factor-α synthesis inhibitor 3,6′-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease J. Neuroinflamm. 9 2012 106
29. V. Villard, J. Espallergues, E. Keller, T. Alkam, A. Nitta, K. Yamada, T. Nabeshima, A. Vamvakides, and T. Maurice Antiamnesic and neuroprotective effects of the aminotetrahydrofuran derivative ANAVEX1-41 against amyloid beta(25-35)-induced toxicity in mice Neuropsychopharmacology 34 6 2009 1552 1566
30. S.C. Vlad, D.R. Miller, N.W. Kowall, and D.T. Felson Protective effects of NSAIDs on the development of Alzheimer disease Neurology 70 19 2008 1672 1677
31. J. Vom Berg, S. Prokop, K.R. Miller, J. Obst, R.E. Kälin, I. Lopategui-Cabezas, A. Wegner, F. Mair, C.G. Schipke, O. Peters, R.Y. Winte, B. Becher, and F.L. Heppner Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline Nat. Med. 18 12 2012 1812 1819
32. T. Wyss-Coray Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med. 12 9 2006 1005 1015
33. C. Zussy, A. Brureau, B. Delair, S. Marchal, E. Keller, G. Ixart, G. Naert, J. Meunier, N. Chevallier, T. Maurice, and L. Givalois Time-course and regional analyses of the physiopathological changes induced after cerebral injection of an amyloid β fragment in rats Am. J. Pathol. 179 1 2011 315-3